Graphical Abstract
![](https://wqketang.oss-cn-beijing.aliyuncs.com/unzip/large-zip/zip-d9683c62-38cf-4d7f-957e-ed3c025b5f47/5765/files/5765-TOC.jpg?Expires=1725755969&OSSAccessKeyId=STS.NT5eViCkqzTYdbfdqxMkjpyyq&Signature=oMpJPqh50fcTRdgb6%2FGxnSAy9lM%3D&security-token=CAISywJ1q6Ft5B2yfSjIr5eALuzdrrRQzZayZkTXgHEtQeRGn7zSkzz2IHtKenhsBOsbtfk1mG5W5%2FgZlqJ9SptIAEfJa9d99MzUP%2FpFltCT1fau5Jko1beHewHKeTOZsebWZ%2BLmNqC%2FHt6md1HDkAJq3LL%2Bbk%2FMdle5MJqP%2B%2FUFB5ZtKWveVzddA8pMLQZPsdITMWCrVcygKRn3mGHdfiEK00he8TouufTinpHMskGA1Aell7Mvyt6vcsT%2BXa5FJ4xiVtq55utye5fa3TRYgxowr%2Fwo0v0YpGya5YzHXwcPskvdKZbo78UqLQlla6w%2BGqFJqvPxr%2Fp8t%2Fx5fWJKAezhVgs8cVM8JOjIqKOscIsiJsO71SmqFV55c8Fdm%2BgUooJVgIMhTnduUfAPJAGOxzJitP%2BUVGGphr60TEnBL4rB5MUctfzRp75SXVPUTzDnGoABjuNLcf76FQN6p3t%2BSlCg%2FxR5C72RIk78k%2BUi44L9ZBmFT6F8GV7aXA52D1Ps56knKF6PAnhRivwyTxgsolycBfvccb3t5jGJ24SgY0aYosAECutxAo7sJhSwlwZvGwGDZJsop1vGiZ8eN1MbtZeRRuMeaZ2I%2BQo%2BnVP6Cf%2F0pDsgAA%3D%3D)
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Respiratory pathogens kill more people than any other infectious agent each year worldwide. Development of novel, economically friendly, sustainable, and highly efficient materials against viruses is a major challenge. Herein, we describe a nanostructured material composed of very small crystalline phosphate copper nanoparticles synthesized using a new biohybrid technology that employs a biological agent for its formation at room temperature in aqueous media. The evaluation of different enzymes in the final preparation of the nanomaterial or even in synthetic methods was performed. Biochemical characterization revealed the formation of Cu species in the protein network. The best biomaterial synthesized using a lipase called BioCuNPs showed excellent inhibition capacity against functional proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); for example, assent 3-chymotrypsin like protease (3CLpro) complete inhibition was achieved by using 5 µg/mL, or acetone (ACE)–spike protein interaction was inhibited by more than 80% in the presence of 400 µg/mL of BioCuNPs. Taking these in vitro results into account, an efficacy analysis against human coronavirus 229E (HCoV-E229) coronavirus was performed. A virus reduction of 99% was obtained in 5 min. Additionally, SARS-CoV-2 virus was tested to demonstrate high efficiency, with > 99% inhibition in 15 min using 500 microgram of material. To determine the wide applicability of this nanohybrid against viruses, an evaluation was carried out against a non-enveloped virus such as Human Rhinovirus (HRV-14), obtaining a virus reduction of 99.9% in 5 min. Finally, the virucidal capacity against different bacteriophages was also evaluated, obtaining an excellent inhibition effect against Phage ΦX174 (99.999% reduction in 5 min).
Warnes, S. L.; Little, Z. R.; Keevil, C. W. Human coronavirus 229E remains infectious on common touch surface materials. mBio 2015, 6, e01697–15.
Lee, K. Y. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int. J. Mol. Sci. 2017, 18, 388.
Morens, D. M.; Fauci, A. S. Emerging pandemic diseases: How we got to COVID-19. Cell 2020, 182, 1077–1092.
Wang, H. H.; Yu, B.; Chen, X. G.; Yan, H. Global pattern and determinants of coronavirus disease 2019 (COVID-19) vaccine coverage and progression: A global ecological study. Glob. Health J. 2023, 7, 18–23.
Sims, S.; Harris, R.; Hussein, S.; Rafferty, A. M.; Desai, A.; Palmer, S.; Brearley, S.; Adams, R.; Rees, L.; Fitzpatrick, J. M. Social distancing and isolation strategies to prevent and control the transmission of COVID-19 and other infectious diseases in care homes for older people: An international review. Int. J. Environ. Health Res. 2022, 19, 3450.
Du, L. Y.; Yang, Y.; Zhang, X. J.; Li, F. Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale 2022, 14, 1054–1074.
Zarrabi, A.; Caldera, F.; Trotta, F. Materials for infectious diseases. Int. J. Mol. Sci. 2023, 24, 3295.
Peng, L. H.; Chen, Y. J.; Yang, S. Y.; Wang, G. J.; Gu, Y. H.; Shen, B. L.; Liu, L. Z.; Xian, R. X.; Li, X. H.; Li, S. Y. et al. Viral contamination on the surfaces of the personal protective equipment among health care professionals working in COVID-19 wards: A single-center prospective, observational study. Am. J. Infect. Control 2023, 51, 276–281.
Bataglioli, R. A.; Rocha Neto, J. B. M.; Calais, G. B.; Lopes, L. M.; Tsukamoto, J.; de Moraes, A. P.; Arns, C. W.; Beppu, M. M. Hybrid alginate-copper sulfate textile coating for coronavirus inactivation. J. Am. Ceram. Soc. 2022, 105, 1748–1752.
Mushtaq, A.; Iqbal, M. Z.; Kong, X. D. Antiviral effects of coinage metal-based nanomaterials to combat COVID-19 and its variants. J. Mater. Chem. B 2022, 10, 5323–5343.
Purwar, T.; Dey, S.; Al-Kayyali, O. Z. A.; Zalar, A. F.; Doosttalab, A.; Castillo, L.; Castano, V. M. Electrostatic spray disinfection using nano-engineered solution on frequently touched surfaces in indoor and outdoor environments. Int. J. Environ. Res. Public Health 2022, 19, 7241.
Mostaghimi, J.; Pershin, L.; Salimijazi, H.; Nejad, M.; Ringuette, M. Thermal spray copper alloy coatings as potent biocidal and virucidal surfaces. J. Therm. Spray Technol. 2021, 30, 25–39.
Kheirabad, A. K.; Pan, X. F.; Long, S. W.; Kochovski, Z.; Zhou, S. Q.; Lu, Y.; McInerney, G.; Yuan, J. Y. Colloidal dispersion of poly(ionic liquid)/Cu composite particles for protective surface coating against SAR-CoV-2. Nano Select 2022, 3, 227–232.
Leite, G. C.; Padoveze, M. C. Copper as an antimicrobial agent in healthcare: An integrative literature review. J. Infect. Control 2012, 1, 33–36.
Michels, H. T.; Michels, C. A. Copper alloys—The new ‘old’ weapon in the fight against infectious disease. Microbiology 2016, 10, 23–45.
Michels, H. T.; Michels, C. A. Can copper help fight COVID-19. Experts on copper and microbiology recommend the expanded use of copper alloys in public spaces to reduce the spread of COVID-19 and minimize future pandemics. Adv. Mater. Process. 2020, 178, 21–25.
Rai, S.; Hirsch, B. E.; Attaway, H. H.; Nadan, R.; Fairey, S.; Hardy, J.; Miller, G.; Armellino, D.; Moran, W. R.; Sharpe, P. et al. Evaluation of the antimicrobial properties of copper surfaces in an outpatient infectious disease practice. Infect. Control Hosp. Epidemiol. 2012, 33, 200–201.
Cortes, A. A.; Zuñiga, J. M. The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review. Diagn. Microbiol. Infect. Dis. 2020, 98, 115176.
Losada-García, N.; Rodriguez-Otero, A.; Palomo, J. M. Tailorable synthesis of heterogeneous enzyme-copper nanobiohybrids and their application in the selective oxidation of benzene to phenol. Catal. Sci. Technol. 2020, 10, 196–206.
Losada-Garcia, N.; Jimenez-Alesanco, A.; Velazquez-Campoy, A.; Abian, O.; Palomo, J. M. Enzyme/nanocopper hybrid nanozymes: Modulating enzyme-like activity by the protein structure for biosensing and tumor catalytic therapy. ACS Appl. Mater. Interfaces 2021, 13, 5111–5124.
Losada-Garcia, N.; Rodriguez-Otero, A.; Palomo, J. M. Fast degradation of bisphenol A in water by nanostructured CuNPs@CALB biohybrid catalyst. Nanomaterials 2020, 10, 7.
Sicchieri, L. B.; Moreira Monteiro, A.; Samad, R. E.; Ito, A. S.; Neto, A. M. F.; Dias Vieira, N. Jr.; Gidlund, M.; Coronato Courrol, L. Study of tryptophan lifetime fluorescence following low-density lipoprotein modification. Appl. Spectrosc. 2013, 67, 379–384.
Hartini, Y.; Saputra, B.; Wahono, B.; Auw, Z.; Indayani, F.; Adelya, L.; Namba, G.; Hariono, M. Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-coronavirus. Results Chem. 2021, 3, 100087.
Benton, D. J.; Wrobel, A. G.; Xu, P. Q.; Roustan, C.; Martin, S. R.; Rosenthal, P. B.; Skehel, J. J.; Gamblin, S. J. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 2020, 588, 327–330.
Kneller, D. W.; Phillips, G.; O'Neill, H. M.; Tan, K.; Joachimiak, A.; Coates, L.; Kovalevsky, A. Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: Insights into enzyme mechanism and drug design. IUCrJ 2020, 7, 1028–1035.
Yang, Y. M.; Zhang, Y. J.; Qu, Y. Y.; Zhang, C.; Liu, X. W.; Zhao, M. W.; Mu, Y. G.; Li, W. F. Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: A molecular dynamics study. Nanoscale 2021, 13, 9364–9370.
Watanabe, Y.; Allen, J. D.; Wrapp, D.; McLellan, J. S.; Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 2020, 369, 330–333.